Lonza Group AG

LSE:0QNO Stock Report

Market Cap: CHF 38.5b

Lonza Group Valuation

Is 0QNO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QNO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QNO (CHF531.88) is trading below our estimate of fair value (CHF1016.95)

Significantly Below Fair Value: 0QNO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QNO?

Key metric: As 0QNO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QNO. This is calculated by dividing 0QNO's market cap by their current earnings.
What is 0QNO's PE Ratio?
PE Ratio67.1x
EarningsCHF 573.00m
Market CapCHF 38.45b

Price to Earnings Ratio vs Peers

How does 0QNO's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QNO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.8x
ERGO Ergomed
46.7x14.2%UK£701.1m
GSK GSK
21.8x23.2%UK£54.7b
HVO hVIVO
7.6x-29.6%UK£132.7m
AZN AstraZeneca
31.2x18.2%UK£161.8b
0QNO Lonza Group
67.1x23.4%CHF 38.5b

Price-To-Earnings vs Peers: 0QNO is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the peer average (20.2x).

Price to Earnings Ratio vs Industry

How does 0QNO's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0QNO 67.1xIndustry Avg. 37.5xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QNO is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the European Life Sciences industry average (37.5x).

Price to Earnings Ratio vs Fair Ratio

What is 0QNO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QNO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.1x
Fair PE Ratio36.9x

Price-To-Earnings vs Fair Ratio: 0QNO is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the estimated Fair Price-To-Earnings Ratio (36.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QNO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 531.88
CHF 636.90
+19.7%
6.8%CHF 723.00CHF 530.00n/a20
Dec ’25CHF 522.23
CHF 632.71
+21.2%
7.7%CHF 760.00CHF 530.00n/a21
Nov ’25CHF 544.08
CHF 631.85
+16.1%
7.9%CHF 760.00CHF 530.00n/a20
Oct ’25CHF 543.40
CHF 624.14
+14.9%
6.4%CHF 700.00CHF 530.00n/a21
Sep ’25CHF 554.28
CHF 619.41
+11.8%
7.0%CHF 700.00CHF 530.00n/a22
Aug ’25CHF 578.80
CHF 613.55
+6.0%
8.0%CHF 700.00CHF 495.00n/a22
Jul ’25CHF 490.41
CHF 586.00
+19.5%
9.4%CHF 666.00CHF 450.00n/a22
Jun ’25CHF 482.00
CHF 576.86
+19.7%
12.1%CHF 655.00CHF 375.00n/a22
May ’25CHF 510.40
CHF 566.00
+10.9%
12.1%CHF 650.00CHF 375.00n/a22
Apr ’25CHF 540.12
CHF 556.00
+2.9%
12.8%CHF 650.00CHF 375.00n/a22
Mar ’25CHF 463.95
CHF 508.25
+9.5%
13.3%CHF 635.00CHF 365.00n/a20
Feb ’25CHF 429.11
CHF 495.20
+15.4%
14.0%CHF 600.00CHF 365.00n/a20
Jan ’25CHF 352.20
CHF 465.16
+32.1%
18.5%CHF 600.00CHF 270.00n/a19
Dec ’24CHF 335.22
CHF 513.11
+53.1%
21.9%CHF 705.00CHF 365.00CHF 522.2319
Nov ’24CHF 318.60
CHF 531.26
+66.7%
20.8%CHF 705.00CHF 365.00CHF 544.0819
Oct ’24CHF 430.02
CHF 627.41
+45.9%
8.5%CHF 705.00CHF 514.00CHF 543.4017
Sep ’24CHF 492.45
CHF 629.83
+27.9%
7.3%CHF 705.00CHF 530.00CHF 554.2818
Aug ’24CHF 503.25
CHF 647.06
+28.6%
6.9%CHF 705.00CHF 570.00CHF 578.8018
Jul ’24CHF 533.08
CHF 679.24
+27.4%
11.1%CHF 900.00CHF 580.00CHF 490.4117
Jun ’24CHF 575.06
CHF 659.84
+14.7%
16.9%CHF 900.00CHF 315.05CHF 482.0018
May ’24CHF 553.84
CHF 663.36
+19.8%
17.1%CHF 900.00CHF 315.05CHF 510.4017
Apr ’24CHF 547.29
CHF 662.77
+21.1%
17.1%CHF 900.00CHF 315.05CHF 540.1217
Mar ’24CHF 560.89
CHF 662.89
+18.2%
16.6%CHF 900.00CHF 315.05CHF 463.9518
Feb ’24CHF 519.56
CHF 659.65
+27.0%
18.0%CHF 935.00CHF 315.05CHF 429.1117
Jan ’24CHF 453.05
CHF 680.88
+50.3%
19.4%CHF 965.00CHF 315.05CHF 352.2016
Dec ’23CHF 508.94
CHF 699.00
+37.3%
17.8%CHF 965.00CHF 315.05CHF 335.2216

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:17
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lonza Group AG is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Volker BosseBaader Helvea Equity Research
Charles Pitman-KingBarclays